Fluidigm Corp (FLDM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Fluidigm Corp (FLDM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH53599D
  • |
  • Pages: 42
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Fluidigm Corp (Fluidigm) formerly Mycometrix Corporation is a biotechnology company that manufactures life-science tools and creates technologies based on microfluidics and mass cytometry. The company's products systems include biomark HD system, access array system, C1 system, callisto system, EP1 system, polaris system, juno system, and helios. It provides custom assays such as SNP type assays, maxplar antibodies, delta gene assays and access array assays. Fluidigm offers software, which include fluidigm cytobank analysis, singular analysis toolset, SNP genotyping analysis, real-time PCR analysis, and digital PCR analysis. The company's C1 system supports mRNA sequencing, DNA sequencing, miRNA analysis and additional applications through the C1 open app IFC. It has presence in the US, France, Canada, Singapore, Japan, Australia, the UK and Germany. Fluidigm is headquartered in South San Francisco, California, the US.

Fluidigm Corp (FLDM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Fluidigm Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Fluidigm Corp, Medical Devices Deals, 2011 to YTD 2017 10

Fluidigm Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Fluidigm Corp, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Fluidigm Enters Into Co-Marketing Agreement With Olink Bioscience For Protein Biomarkers 12

Fluidigm Enters Into Co-Development Agreement With DKMS For High Throughput HLA Typing System 13

Genome Institue of Singapore Partners With Fluidigm To Establish Single-Cell Genomics Research Center 14

DVS Sciences And Cytobank Enter Into Co-Development Agreement 15

Equity Offering 15

Fluidigm Completes Public Offering Of Common Stock For US$60 Million 15

Fluidigm Completes IPO Of Common Stock For US$86.3 Million 17

Debt Offering 18

Fluidigm Completes Public Offering Of Notes Due 2034 For US$201.3 Million 18

Fluidigm Corp-Key Competitors 20

Key Employees 21

Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Strategy And Business Planning 23

Aug 04, 2016: Fluidigm Introduces New High-Throughput Targeted NGS Library Preparation System 23

Jun 09, 2016: Fluidigm Announces New Customer Inspiration Center in Canada for Mass Cytometry 24

Financial Announcements 25

Feb 08, 2017: Fluidigm Announces Q4 And Full Year 2016 Financial Results 25

Jan 09, 2017: Fluidigm Announces Preliminary Revenue For The Fourth Quarter And Full Year 27

Nov 03, 2016: Fluidigm Announces Third Quarter Financial Results 28

Oct 12, 2016: Fluidigm Announces Preliminary Third Quarter 2016 Revenue 30

Aug 04, 2016: Fluidigm Announces Q2 2016 Financial Results 31

May 05, 2016: Fluidigm Announces First Quarter Financial Results 33

Feb 04, 2016: Fluidigm Announces Q4-Full Year 2015 Financial Results 35

Jan 12, 2016: Fluidigm Announces Preliminary Full Year and Fourth Quarter 2015 Revenue 36

Corporate Communications 37

Mar 27, 2017: Nicolas Barthelemy and Carlos Paya Join Fluidigm Board of Directors 37

Oct 19, 2016: Fluidigm Names S. Christopher Linthwaite as New Chief Executive Officer 38

Aug 04, 2016: Fluidigm Appoints New President and Chief Operating Officer 39

Legal and Regulatory 40

Aug 04, 2016: Fluidigm Receives ISO 13485 And ISO 9001 Certification 40

Product News 41

Dec 21, 2016: Fluidigm Introduces A New Medium-Cell High-Throughput Integrated Fluidic Circuit 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42

List of Figures

Fluidigm Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Fluidigm Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Fluidigm Corp, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Fluidigm Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Fluidigm Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Fluidigm Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Fluidigm Corp, Deals By Therapy Area, 2011 to YTD 2017 9

Fluidigm Corp, Medical Devices Deals, 2011 to YTD 2017 10

Fluidigm Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Fluidigm Enters Into Co-Marketing Agreement With Olink Bioscience For Protein Biomarkers 12

Fluidigm Enters Into Co-Development Agreement With DKMS For High Throughput HLA Typing System 13

Genome Institue of Singapore Partners With Fluidigm To Establish Single-Cell Genomics Research Center 14

DVS Sciences And Cytobank Enter Into Co-Development Agreement 15

Fluidigm Completes Public Offering Of Common Stock For US$60 Million 15

Fluidigm Completes IPO Of Common Stock For US$86.3 Million 17

Fluidigm Completes Public Offering Of Notes Due 2034 For US$201.3 Million 18

Fluidigm Corp, Key Competitors 20

Fluidigm Corp, Key Employees 21

Fluidigm Corp, Other Locations 22

Fluidigm Corp, Subsidiaries 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Fluidigm Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16120
Site License
USD 500 INR 32240
Corporate User License
USD 750 INR 48360

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com